Impact of Different Metabolic Indicators on Ventricular Repolarization Indices in Obese Children: A Case Control

Asmaa A El Sehmawy1, Rasha Abd El Samad Fawaz1, Nadia Ahmed Agiba2

  • 1Pediatrics Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

Insights

Obese children show prolonged ventricular repolarization, indicated by increased JTc and QTc dispersion, linked to higher BMI and insulin resistance.

Area of Science:

  • Pediatric Cardiology
  • Metabolic Disorders
  • Electrophysiology

Background:

  • Obesity, insulin resistance, and dyslipidemia are potential factors affecting ventricular repolarization in children.
  • Understanding these impacts is crucial for pediatric cardiovascular health.

Purpose of the Study:

  • To investigate the relationship between metabolic indicators and ventricular repolarization in obese children compared to healthy controls.
  • To identify specific ECG parameters affected by obesity and metabolic dysfunction in pediatric populations.

Main Methods:

  • A case-control study involving 90 children (45 obese, 45 normal weight).
  • Analysis of 12-lead electrocardiograms (ECGs) for corrected QT (QTc), QTc dispersion (QTcd), JTc dispersion, and TpTe interval.
  • Assessment of lipid profiles, fasting plasma glucose (FPG), and serum insulin to calculate Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).

Main Results:

  • Obese children exhibited significantly higher triglycerides, cholesterol, LDL, fasting insulin, and HOMA-IR.
  • Obese children showed significantly longer QTcd and JTcd intervals.
  • Positive correlations were found between QTcd/JTc dispersion and waist circumference, BMI, blood pressure, fasting insulin, HOMA-IR, and LDL.

Conclusions:

  • Obese children demonstrate increased JTc and QTc dispersion, correlating with waist circumference, BMI, and insulin resistance.
  • Ventricular repolarization abnormalities in obese children are linked to metabolic dysregulation.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...